Physician profile
Frank Tzeng
NPI 1932292315
$1,860.74
in general payments reported to CMS, 2019-2025
13 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $136 · 2021: $133 · 2022: $124 · 2023: $14.52 · 2024: $28.25 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.90 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $421.14 | 2019-2022 | |
| Abbott Laboratories | $309.41 | 2025 | Freestyle Libre 3 |
| Radius Health, INC. | $226.15 | 2019-2024 | Tymlos |
| Amgen INC. | $154.42 | 2019-2025 | Tepezza |
| Astrazeneca Pharmaceuticals LP | $129.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.72 | 2019 | |
| Pfizer INC. | $119.25 | 2020 | |
| Insulet Corporation | $117.42 | 2019 | |
| Boston Scientific Corporation | $116.22 | 2021 | |
| Dexcom, INC. | $59.56 | 2021-2025 | Dexcom G6 Transmitter |
| Shire North American Group INC | $47.97 | 2019 | |
| Oxford Immunotec USA INC | $23.08 | 2019 | |
| Merck Sharp & Dohme LLC | $16.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Tzeng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.